Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib vs pembrolizumab + lenvatinib in first-line advanced clear cell renal cell carcinoma
jRCT2031210435Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Keytruda + belzutifan + lenvatinib, MK-1308A + lenvatinib and Keytruda + lenvatinib (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started Dec 2021; status: active, not recruiting.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on jRCT2031210435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210435.